《新股消息》友芝友生物-B(02496.HK)今起招股 一手入場費4,040元
友芝友生物-B(02496.HK)公布招股詳情,擬全球發售1,100.12萬股H股,香港公開發售佔一成,國際發售佔九成。每股招股價介乎16至20元。每手200股計,一手入場費4,040.35元。該股今日(13日)起招股,下周一(18日)中午截止,預期9月25日掛牌。獨家保薦人為中信建投國際。
公司上市引入三名基石投資者,包括光谷健康、楚興友瑞及樸華凱智,擬認購約1.06億元公司股份。
如以招股價中位數18元計,公司上市料淨集資約1.42億元,當中約80%將用作核心產品M701計劃進行的臨床試驗、擬備註冊備案文件及商業化推出計劃(包括銷售和市場推廣活動);約12%將用作Y101D計劃進行的臨床試驗;約8%將用作營運資金和一般公司用途。
友芝友生物為致力於開發用於治療癌症相關併發症、癌症及老年性眼科疾病的雙特異性抗體(BsAb)療法的生物技術公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.